drugset
drugset / Trial / NCT05535647

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

NCT05535647 ↗

Phase 2 Unknown 60 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a prospective, Two-arm, comparative, randomized, controlled phase II trial, to explore the efficacy and safety of Regorafenib and HAIC vs. FOLFOX as Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma.

Timeline

Start
2022-09-25
Primary completion
2024-09-25
Completion
2025-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxa Unknown 85 mg/m2 Other
Subject Regorafenib Small molecule 80 mg Oral
Subject Regorafenib Small molecule 400 mg/m2 Other
Subject fluorouracil Small molecule 400 mg/m2 Other
Subject fluorouracil Small molecule 2400 mg/m2 Other

Indications

intrahepatic cholangiocarcinoma